DISEASE SCANNER
Global Incurable Diseases Tracker
Glioblastoma Multiforme (GBM)
The most common and aggressive malignant primary brain tumor in adults. Characterized by necrosis, microvascular proliferation, and cellular atypia. Median survival 15-18 months with standard treatment despite aggressive therapy. IDH-wildtype is most common.
250.0K
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Biopsy
- 2Imaging (CT, MRI, PET)
- 3Tumor markers
- 4Genetic testing
- 5Endoscopy
- 6Blood tests
- 7Screening programs
Prognosis
Despite multimodal therapy (surgery, radiation, temozolomide), median survival is 15-18 months. 2-year survival is 25-30%. 5-year survival is <10%. MGMT promoter methylation predicts better response to temozolomide (23 vs 12 months). Gross total resection adds 3-6 months survival. Bevacizumab improves progression-free survival but not overall survival. Tumor-treating fields (Optune) add 4-5 months. Recurrent disease has median survival of 6-9 months.
Prevention
- Smoking cessation
- Sun protection
- Healthy diet
- Regular exercise
- Vaccination (HPV, HBV)
- Screening programs
- Limit alcohol
- Maintain healthy weight
Research Status
Tumor Treating Fields (Optune) approved. CAR-T therapies, oncolytic viruses (DNX-2401), and personalized vaccines in trials. Standard of care: maximal safe resection, radiation, temozolomide. MGMT methylation predictive.
Affected Countries
Sources
- https://www.cancer.gov
- https://www.who.int/cancer
- https://www.cancer.org
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.